Exploring Therapeutic Targets of the Beta Amyloid Pathway to Slow the Progression of Alzheimer Disease

https://www.pharmacytimes.org/on-demand/exploring-therapeutic-targets-of-the-beta-amyloid-pathway-to-slow-the-progression-of-alzheimer-disease

Related Videos

Related Content

Advertisement

May 22nd 2025

Patient-Reported Experiences Show Psychological Impact of Atopic Dermatitis on Adolescents

AJMC Contributor

The findings, which add to the limited data on the burden of atopic dermatitis on adolescent and pediatric patients, showed differences in what was most bothersome to the younger group of patients.

May 20th 2025

Mental Health Awareness: Transforming Workplace Support and Engagement

Giuliana Grossi Jim Kinville

Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.

May 22nd 2025

AI Can Boost Accuracy When Classifying HER2-Low, HER2-Ultralow Breast Cancers, Findings Show

Mary Caffrey

Assistance from artificial intelligence can potenially increase the number of patients eligible for treatment for HER2-low breast cancers.

May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS

Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.

May 22nd 2025

Safety, Efficacy of Luspatercept for MDS Confirmed in Real-World Setting

Rose McNulty

Luspatercept showed real-world efficacy among patients with lower-risk myelodysplastic syndrome (MDS), confirming results seen in clinical trials.

May 22nd 2025

Evernorth Launches Co-Pay Cap for Weight Loss Drugs Amid New Federal Drug Pricing Effort

Brooke McCormick

Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug pricing initiatives.

Related Content

Advertisement

May 22nd 2025

Patient-Reported Experiences Show Psychological Impact of Atopic Dermatitis on Adolescents

AJMC Contributor

The findings, which add to the limited data on the burden of atopic dermatitis on adolescent and pediatric patients, showed differences in what was most bothersome to the younger group of patients.

May 20th 2025

Mental Health Awareness: Transforming Workplace Support and Engagement

Giuliana Grossi Jim Kinville

Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.

May 22nd 2025

AI Can Boost Accuracy When Classifying HER2-Low, HER2-Ultralow Breast Cancers, Findings Show

Mary Caffrey

Assistance from artificial intelligence can potenially increase the number of patients eligible for treatment for HER2-low breast cancers.

May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS

Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.

May 22nd 2025

Safety, Efficacy of Luspatercept for MDS Confirmed in Real-World Setting

Rose McNulty

Luspatercept showed real-world efficacy among patients with lower-risk myelodysplastic syndrome (MDS), confirming results seen in clinical trials.

May 22nd 2025

Evernorth Launches Co-Pay Cap for Weight Loss Drugs Amid New Federal Drug Pricing Effort

Brooke McCormick

Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug pricing initiatives.